Abstract | BACKGROUND: METHODS: The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in NR1D1 for the following association analysis. RESULTS: We did not detect a significant association between NR1D1 and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. CONCLUSION: Our results suggest that NR1D1 does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.
|
Authors | Taro Kishi, Tsuyoshi Kitajima, Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Tomo Okochi, Norio Ozaki, Nakao Iwata |
Journal | Neuropsychobiology
(Neuropsychobiology)
Vol. 59
Issue 4
Pg. 234-8
( 2009)
ISSN: 1423-0224 [Electronic] Switzerland |
PMID | 19571598
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2009 S. Karger AG, Basel. |
Chemical References |
- Antidepressive Agents, Second-Generation
- NR1D1 protein, human
- Nuclear Receptor Subfamily 1, Group D, Member 1
- Receptors, Cytoplasmic and Nuclear
- Fluvoxamine
|
Topics |
- Adult
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Depressive Disorder, Major
(drug therapy, genetics)
- Female
- Fluvoxamine
(therapeutic use)
- Gene Frequency
- Genotype
- Haplotypes
- Humans
- Japan
- Linkage Disequilibrium
- Male
- Middle Aged
- Nuclear Receptor Subfamily 1, Group D, Member 1
- Polymorphism, Single Nucleotide
- Receptors, Cytoplasmic and Nuclear
(genetics)
- Remission Induction
- Sequence Analysis, DNA
- Severity of Illness Index
- Treatment Outcome
|